Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Analysis & Investment Frameworks
Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock analysis on Invetso. Review Cadrenal Therapeutics, Inc. Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cadrenal Therapeutics, Inc. Common Stock Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Cadrenal Therapeutics, Inc. Common Stock Key Financial Metrics
- Market Cap: $3.57M
- Revenue: $N/A
- ROE: -406.38%
- ROIC: -284.81%
- Dividend Yield: N/A
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. Common Stock Investment Frameworks
Invetso analyzes Cadrenal Therapeutics, Inc. Common Stock (CVKD) across the following frameworks:
- Cadrenal Therapeutics, Inc. Common Stock 10Y Growth Potential
- Cadrenal Therapeutics, Inc. Common Stock Scenario Analysis
- Cadrenal Therapeutics, Inc. Common Stock Risks & Opportunities
- Cadrenal Therapeutics, Inc. Common Stock Economic Moat
- Cadrenal Therapeutics, Inc. Common Stock Business Model
- Cadrenal Therapeutics, Inc. Common Stock Management
- Cadrenal Therapeutics, Inc. Common Stock SWOT Analysis
- Cadrenal Therapeutics, Inc. Common Stock Porter's 5 Forces
- Cadrenal Therapeutics, Inc. Common Stock PESTLE Analysis
- Cadrenal Therapeutics, Inc. Common Stock ESG Analysis